PFU THERAPEUTICS LTD
PFU Therapeutics Ltd is a pre-clinical UK biotech developing RNA-based gene therapies via its proprietary SYNTHESOMES nanoparticle delivery platform, targeting muscle health in metabolic disease, obesity, and rare neuromuscular conditions.
- Company typePrivate
- Founded2023
- HeadquartersHarrow, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What PFU THERAPEUTICS LTD does
PFU Therapeutics Ltd is a privately held, pre-clinical biotechnology company founded in 2023 and based in Harrow, United Kingdom. The company is developing RNA-based gene therapies using a proprietary platform called SYNTHESOMES, described as a synthetic multivalent nanoparticle system designed for high-efficiency delivery of multiple therapeutic oligonucleotides. PFU's scientific thesis centers on muscle biology as a shared mechanism linking two therapeutic verticals: metabolic disease and obesity care (positioned within the GLP-1 era) and rare neuromuscular diseases. The intended patient populations are individuals suffering from metabolic dysfunction, muscle loss conditions, obesity-related muscle health issues, and rare neuromuscular diseases such as FSHD. The company frames its value proposition around restoring muscle strength and augmenting muscle mass through targeted RNA medicine delivery.
PFU operates with a headcount of 1-10 and has no disclosed commercial products, no pricing, no distribution channels, no partnerships, and no disclosed funding rounds. Its only public-facing assets are a corporate website (pfutx.com) describing the platform and a generic contact channel. The business model is therefore best characterized as an early-stage R&D-stage biotech seeking to validate a delivery platform before any commercialization, partnership monetization, or licensing activity. No leadership team, advisory board, investors, patents, or regulatory milestones are disclosed in the available data, which constrains any inference about near-term operational traction. The core commercial question is whether the SYNTHESOMES platform can attract pharma partnership interest or grant funding sufficient to advance from concept to in-vivo validation.
PFU THERAPEUTICS LTD firmographics
Firmographics- Name
- PFU THERAPEUTICS LTD
- Legal name
- PFU Therapeutics
- Website
- https://pfutx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PFU Therapeutics Ltd is a pre-clinical UK biotech developing RNA-based gene therapies via its proprietary SYNTHESOMES nanoparticle delivery platform, targeting muscle health in metabolic disease, obesity, and rare neuromuscular conditions.
- Ownership category
- akta.pro rank
PFU THERAPEUTICS LTD industry classification
Industry- Product category
- Biotechnology Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
Keywords
Where PFU THERAPEUTICS LTD is headquartered
LocationHeadquarters
- HQ city
- Harrow
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
PFU THERAPEUTICS LTD business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Marketing channels1 record
PFU THERAPEUTICS LTD product offering
Product offeringCore offering
PFU Therapeutics develops RNA-based gene therapies using its proprietary SYNTHESOMES synthetic multivalent nanoparticle platform, which enables high-efficiency delivery of multiple therapeutic oligonucleotides. The company's pipeline targets muscle health, specifically augmenting muscle mass to link GLP-1 era obesity care with rare neuromuscular innovation through shared muscle biology, and addresses metabolic and rare muscle-related diseases.
Product overview
PFU Therapeutics is developing a gene therapy platform centered on SYNTHESOMES, a synthetic multivalent nanoparticle platform designed for high-efficiency delivery of multiple therapeutic oligonucleotides. The company's approach focuses on muscle health for metabolic and rare diseases, specifically augmenting muscle mass in obesity care and rare neuromuscular conditions. The technology enables RNA medicine delivery targeting muscle biology.
Differentiator
Problem solved
Functional benefit
Products and services
- SYNTHESOMES SYNTHESOMES is PFU Therapeutics' proprietary synthetic multivalent nanoparticle platform designed for high-efficiency delivery of multiple therapeutic oligonucleotides in RNA-based gene therapy applications. It targets muscle health across metabolic and rare neuromuscular disease indications, with the stated aim of augmenting muscle mass and linking GLP-1 era obesity care with rare neuromuscular innovation through shared muscle biology. The platform is intended for scientific and biopharmaceutical partners developing RNA medicines for muscle-related conditions.
Companies that use PFU THERAPEUTICS LTD
Customer profileSegments1 record
Ideal customer profiles1 record
PFU THERAPEUTICS LTD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PFU THERAPEUTICS LTD partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights2 records
PFU THERAPEUTICS LTD competitors and assessment
Company assessmentDirect peers
- Dyne Therapeutics: Dyne Therapeutics is developing oligonucleotide-based therapies for serious muscle diseases using a proprietary FORCE platform targeting muscle. Directly comparable to PFU's SYNTHESOMES approach of muscle-targeted oligonucleotide delivery for rare neuromuscular conditions.
- PepGen: PepGen develops enhanced delivery oligonucleotides for neuromuscular diseases, including Duchenne muscular dystrophy and DM1. Directly comparable as a muscle-focused oligonucleotide delivery company pursuing similar rare disease indications.
- Avidity Biosciences: Avidity is pioneering Antibody Oligonucleotide Conjugates (AOCs) for muscle and other diseases, including myotonic dystrophy and FSHD. Highly comparable as a muscle-targeted RNA therapeutics company addressing similar rare neuromuscular indications.
- Capricor Therapeutics: Capricor is developing cell-based and exosome-based therapies for Duchenne muscular dystrophy and other muscle diseases. Comparable as a therapeutics developer targeting muscle biology in rare neuromuscular diseases.
- Entrada Therapeutics: Entrada develops intracellular delivery vehicles for oligonucleotide and protein therapeutics, including for Duchenne muscular dystrophy and DM1. Comparable as a company pioneering novel delivery approaches for muscle-targeted RNA medicines.
- Solid Biosciences: Solid Biosciences develops gene therapies for Duchenne muscular dystrophy and other neuromuscular disorders using AAV-based delivery. Comparable as a muscle-targeted gene therapy company addressing overlapping rare neuromuscular indications.
Broad incumbents
- Alnylam Pharmaceuticals: Alnylam is a leader in RNAi therapeutics with established platforms for siRNA delivery. Comparable as a broad incumbent in RNA therapeutics whose delivery technology and pipeline establish the competitive benchmark for novel platforms like SYNTHESOMES.
- Ionis Pharmaceuticals: Ionis is a pioneer in antisense oligonucleotide (ASO) therapeutics with deep expertise across neurological and metabolic diseases. Comparable as a broad RNA therapeutics incumbent whose technology and pipeline overlap with PFU's therapeutic modality and target indications.
- Sarepta Therapeutics: Sarepta is an established gene therapy leader for Duchenne muscular dystrophy and other neuromuscular diseases, with approved and clinical-stage assets. Comparable as a major player in muscle-targeted genetic medicines competing for the same patient populations.
- BioMarin Pharmaceutical: BioMarin is an established rare disease biotech with a portfolio spanning enzyme replacement and gene therapies, including muscular dystrophy programs. Comparable as a broad incumbent in rare disease therapeutics targeting overlapping patient populations.
Market position
Weaknesses1 record
Competitive moat1 record
Key risks6 records
Key highlights5 records
Customer concentration
PFU THERAPEUTICS LTD social profiles
Digital presencePFU THERAPEUTICS LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
PFU THERAPEUTICS LTD leadership team
Management profileNumber of profiles
PFU THERAPEUTICS LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PFU THERAPEUTICS LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PFU THERAPEUTICS LTD
What does PFU THERAPEUTICS LTD do?
PFU Therapeutics develops RNA-based gene therapies using its proprietary SYNTHESOMES synthetic multivalent nanoparticle platform, which enables high-efficiency delivery of multiple therapeutic oligonucleotides. The company's pipeline targets muscle health, specifically augmenting muscle mass to link GLP-1 era obesity care with rare neuromuscular innovation through shared muscle biology, and addresses metabolic and rare muscle-related diseases.
Is PFU THERAPEUTICS LTD a public or private company?
PFU THERAPEUTICS LTD is a private company. It is classified as unknown and is currently operating.
When was PFU THERAPEUTICS LTD founded?
PFU THERAPEUTICS LTD was founded in 2023. It employs 1 to 10 people.
Where is PFU THERAPEUTICS LTD based?
PFU THERAPEUTICS LTD is headquartered in Harrow, United Kingdom, in the Europe region.
Who are PFU THERAPEUTICS LTD's main competitors?
Direct peers on record are Dyne Therapeutics, PepGen, Avidity Biosciences, Capricor Therapeutics, Entrada Therapeutics and Solid Biosciences. Broad incumbents are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics and BioMarin Pharmaceutical.
Does PFU THERAPEUTICS LTD have an API?
No public API is recorded for PFU THERAPEUTICS LTD.
What industry is PFU THERAPEUTICS LTD in?
PFU THERAPEUTICS LTD's product category is Biotechnology Research. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 541714.